NXTC Q3 2023 Earnings — NextCure, Inc. Revenue & Financial Results | Market Cap Arena

NXTCNextCure, Inc.

$36M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$16M

Net Income

-$14M

EPS (Diluted)

$-6.16

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$140M

Total Liabilities

$13M

Stockholders' Equity

$126M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$16M	-$19M	+18.8%
Net Income	-$14M	-$19M	+24.4%